6 completed. 3 Phase 2, 3 Phase 3.
By phase and status
Follow APL-130277: new trials by email Literature Review of APL-130277 trials Research Report on APL-130277
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) APL-130277, subcutaneous apomorphine - Motor OFF Episodes Associated With Parkinson's Disease | Phase 3 | Completed | 113 | 2018-12-19 | 2022-12-16 |
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes APL-130277, APO-go, Apokyn - Parkinson Disease | Phase 2 | Completed | 8 | 2017-08-22 | 2020-08-13 |
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes APL-130277, Placebo, Moxifloxacin - Parkinson's Disease, Off Episodes of Parkinson Disease | Phase 2 | Completed | 48 | 2017-08-03 | 2020-08-10 |
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease APL-130277 - Parkinson Disease | Phase 3 | Completed | 496 | 2015-08-31 | 2023-11-22 |
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease APL-130277, Placebo - Parkinson Disease, Off Episodes | Phase 3 | Completed | 141 | 2015-06-18 | 2020-07-30 |
A Study to Examine APL-130277 in Patients With Parkinson's Disease APL-130277 - Parkinson's Disease | Phase 2 | Completed | 20 | 2014-08-31 | 2020-07-30 |
Conditions studied
Parkinson Disease (6)
Sponsors
Sumitomo Pharma America, Inc. (6)
Countries
United States (5) · Italy (3) · Austria (2) · Canada (2) · France (2) · Germany (2) · Spain (2) · United Kingdom (2)
Results publications
PMID 31818699, PMID 33991326, PMID 35899977
NIH funding
2016 (3)